- Home
- EDRY vs SCLX Comparison
EDRY vs SCLX Comparison
Compare EDRY & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDRY
- SCLX
- Stock Information
- Founded
- EDRY 2018
- SCLX 2011
- Country
- EDRY Greece
- SCLX United States
- Employees
- EDRY N/A
- SCLX N/A
- Industry
- EDRY Marine Transportation
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- EDRY Consumer Discretionary
- SCLX Health Care
- Exchange
- EDRY Nasdaq
- SCLX Nasdaq
- Market Cap
- EDRY 34.8M
- SCLX 35.7M
- IPO Year
- EDRY N/A
- SCLX N/A
- Fundamental
- Price
- EDRY $12.66
- SCLX $18.73
- Analyst Decision
- EDRY
- SCLX Strong Buy
- Analyst Count
- EDRY 0
- SCLX 3
- Target Price
- EDRY N/A
- SCLX $367.50
- AVG Volume (30 Days)
- EDRY 6.8K
- SCLX 309.9K
- Earning Date
- EDRY 11-18-2025
- SCLX 08-13-2025
- Dividend Yield
- EDRY N/A
- SCLX N/A
- EPS Growth
- EDRY N/A
- SCLX N/A
- EPS
- EDRY N/A
- SCLX N/A
- Revenue
- EDRY $49,707,775.00
- SCLX $44,236,000.00
- Revenue This Year
- EDRY N/A
- SCLX $89.26
- Revenue Next Year
- EDRY $28.45
- SCLX $203.95
- P/E Ratio
- EDRY N/A
- SCLX N/A
- Revenue Growth
- EDRY N/A
- SCLX N/A
- 52 Week Low
- EDRY $7.60
- SCLX $3.60
- 52 Week High
- EDRY $20.79
- SCLX $39.90
- Technical
- Relative Strength Index (RSI)
- EDRY 60.31
- SCLX 46.04
- Support Level
- EDRY $12.29
- SCLX $14.80
- Resistance Level
- EDRY $12.89
- SCLX $30.90
- Average True Range (ATR)
- EDRY 0.68
- SCLX 3.47
- MACD
- EDRY -0.05
- SCLX -1.47
- Stochastic Oscillator
- EDRY 29.41
- SCLX 23.68
About EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.